Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Non-Current Liabilities (2022 - 2025)

BioXcel Therapeutics has reported Total Non-Current Liabilities over the past 4 years, most recently at $138.6 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $138.6 million for Q4 2025, up 11.04% from a year ago — trailing twelve months through Dec 2025 was $138.6 million (up 11.04% YoY), and the annual figure for FY2025 was $138.6 million, up 11.04%.
  • Total Non-Current Liabilities for Q4 2025 was $138.6 million at BioXcel Therapeutics, up from $130.1 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for BTAI hit a ceiling of $139.0 million in Q3 2023 and a floor of $82.0 million in Q2 2022.
  • Median Total Non-Current Liabilities over the past 4 years was $130.1 million (2025), compared with a mean of $126.2 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 61.19% in 2023 and later dropped 6.38% in 2024.
  • BioXcel Therapeutics' Total Non-Current Liabilities stood at $126.7 million in 2022, then increased by 1.24% to $128.3 million in 2023, then decreased by 2.73% to $124.8 million in 2024, then increased by 11.04% to $138.6 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $138.6 million (Q4 2025), $130.1 million (Q3 2025), and $130.8 million (Q2 2025) per Business Quant data.